MYDA Advisors’s Cardlytics CDLX Stock Holding History

MYDA Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$289K	–	120
2022 Q4	$289K	Buy	+5,000	New	+$309K	0.18%	65

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GEH

General Equity Holdings Brooklyn, New York $135M AUM 32.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

MYDA Advisors's CDLX Position: Q1 2023 in Review

MYDA Advisors sold out of Cardlytics (CDLX) in Q1 2023, closing a stake of 5,000 shares — an estimated $289K sold.

MYDA Advisors first reported a position in CDLX in Q4 2022 and held it in 1 quarter. The position peaked at $289K in Q4 2022. 103 funds tracked by Wall St. Rank hold CDLX as of Q1 2023.

MYDA Advisors reported no remaining Cardlytics position as of Q1 2023 after selling out during the quarter.
MYDA Advisors sold 5,000 Cardlytics shares in Q1 2023, an estimated $289K.
MYDA Advisors first reported a position in Cardlytics in Q4 2022 and held it in 1 quarter.
MYDA Advisors's Cardlytics position peaked at $289K in Q4 2022.
103 funds tracked by Wall St. Rank held Cardlytics as of Q1 2023.

Based on MYDA Advisors's 13F filing for Q1 2023, filed 12 May 2023.